Horwitz D, Thorgeirsson S S, Mitchell J R
Eur J Clin Pharmacol. 1977 Oct 14;12(2):133-6. doi: 10.1007/BF00645134.
Administration of allopurinol 300 mg/day produced minimal changes in the disappearance of phenylbutazone in each of five subjects following single doses (6 mg/kg) in clinical range and caused some prolongation (21%, 52%) of drug half-lives in two of six subjects after single small doses (0.5 mg/kg); mean half-life was not significantly altered by allopurinol at either dose level (means of 52 versus 48 at 0.5 mg/kg and 68 versus 70 h at 6 mg/kg). Size of dose altered half-life when phenylbutazone was used alone; three subjects showed considerably longer half-lives at the higher dose (86 versus 47, 91 versus 41, 65 versus 38 h). Allopurinol caused a greater than 50% prolongation of half-lives in two of five subjects who received single 0.5 g doses of probenecid. These preliminary data do not indicate a need to change the dose of phenylbutazone when subjects are receiving allopurinol.
在五名受试者单次给予临床剂量范围的苯基丁氮酮（6毫克/千克）后，每天服用300毫克别嘌醇对苯基丁氮酮的消除产生的变化极小；在六名受试者中的两名单次给予小剂量（0.5毫克/千克）后，别嘌醇使药物半衰期延长了一些（分别为21%、52%）；在任一剂量水平下，别嘌醇均未显著改变平均半衰期（0.5毫克/千克时分别为52小时和48小时，6毫克/千克时分别为68小时和70小时）。单独使用苯基丁氮酮时，剂量大小会改变半衰期；三名受试者在较高剂量下的半衰期明显更长（分别为86小时对47小时、91小时对41小时、65小时对38小时）。在五名接受单次0.5克丙磺舒剂量的受试者中，有两名受试者的半衰期因别嘌醇而延长超过50%。这些初步数据表明，当受试者接受别嘌醇治疗时，无需改变苯基丁氮酮的剂量。
